InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-21.3%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Kantoff Aaron, Director. Director active across 3 companies, notably Centessa Pharmaceuticals plc. Cumulatively, 8 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €190k. Activity tracked since 18 November 2021. The latest transaction was disclosed on 24 October 2025 (Don). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Kantoff Aaron
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
3,166 sharesCommon StockSEC:0001862734-26-000002:0
88,281 sharesCommon StockSEC:0001862734-25-000006:0
5,000 shares0Common StockSEC:0001862734-25-000004:0
37,890 shares@ US$0.134.8% of flowCommon StockSEC:0001415889-25-023997:0
3,167 sharesCommon StockSEC:0001578563-25-000201:0
7,500 shares@ US$11.86100.0% of flowCommon StockSEC:0001209191-23-053674:0
Canonical exit: 22 Jan 2024 (T+90)
37,891 sharesCommon StockSEC:0001209191-23-053397:0
10,000 shares@ US$11.985100.0% of flowOrdinary SharesSEC:0000899243-21-045321:0
Canonical exit: 16 Feb 2022 (T+90)
8 of 8 declarations
About Kantoff Aaron
KANTOFF AARON is Administrateur at Tourmaline Bio, Inc., Avalo Therapeutics, Inc. and Centessa Pharmaceuticals plc. Across 8 filings in total, the 8 sampled filings cover the period from 2021-11-18 to 2026-03-31, with EUR 189815 of buys and EUR 0 of sells, and the most common transaction nature is Levée d'options.
